Maggie Smith, Dnp, Msn/Ed, Rn, Ocn
About Maggie Smith, Dnp, Msn/Ed, Rn, Ocn
Maggie Smith, DNP, MSN/Ed, RN, OCN, is the Region Associate Director, West Oncology MSLs at Bristol Myers Squibb with extensive experience in oncology and medical science liaison roles.
Title
Maggie Smith currently serves as the Region Associate Director, West Oncology MSLs at Bristol Myers Squibb. Her role involves overseeing medical science liaisons in the western region, focusing on oncology.
Current Company
Maggie Smith works at Bristol Myers Squibb, a leading global biopharmaceutical company. In her capacity as Region Associate Director, West Oncology MSLs, she plays a crucial role in leading field-based medical liaisons specializing in oncology.
Previous Experience
Maggie Smith has an extensive background in oncology spanning over two decades. Before joining Bristol Myers Squibb, she held the position of National Director at Kyowa Kirin, overseeing North America's Oncology Medical Science Liaisons. At Pfizer, she worked as Field Medical Director, GU Oncology. She spent a decade at Janssen Inc. as Principal Medical Science Liaison in Hematology/Oncology. Other notable roles include Senior Medical Science Liaison at Hospira and Clinical Support Specialist at Carmel Pharma.
Education and Expertise
Maggie Smith holds a Doctor of Nursing Practice from Marciella Niehoff School of Nursing at Loyola University, a Master's degree from the University of Phoenix, and a Bachelor of Nursing degree from Chicago State University. Her expertise spans bone marrow transplantation, hematology/oncology, and immuno-oncology, specializing in various malignancies and healthcare protocol development.
Leadership and Professional Involvement
Maggie Smith has served on various national and local oncology boards and committees, contributing to advancements in oncology care and health policies. She has led multiple leadership projects and mentored professionals within the oncology field. Her experience includes involvement in different phases of clinical research and new drug and device launches in the pharmaceutical industry.